In this interview, the Managing Director of Cooper Metals (ASX:CPM) discusses the company's active drilling program in the Mount Isa region, targeting copper and gold prospects. They highlight their methodical approach to exploration, emphasizing the importance of ground truthing and geochemical/geophysical data in delineating robust drill targets. The interview also covers their "scout drilling campaign" and the anticipation of assay results. Cooper Metals' expansion into new tenements near the Eloise Deposit and plans for the future are highlighted, and their commitment to keeping stakeholders informed remains a key focus throughout the conversation.
Copyright 2023 – Finance News Network
06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund’s composition and outlook for the next 6 months and longer term.
25 Oct 2024 - In the keynote address for the inaugural Semiconductor Australia conference, Digital Playground Co-Founder and General Partner Peter Barrett discusses Australia's potential to lead in next-generation technology.
18 Sep 2024 - Venkata Gutta, CEO and Founder of MILLIBEAM, discusses the company’s mission to make millimetre-wave technology cost-effective and scalable.
28 Feb 2024 - Chris Stevens - Chief Executive Officer & Executive Director - Coda Minerals (ASX:COD) is an advanced exploration company primed to unlock the value of the highly prospective Elizabeth Creek Copper Cobalt Project in South Australia’s world class mining jurisdiction, the Gawler Craton.
17 May 2022 - PropTech Group Limited (ASX:PTG) Managing Director and Group CEO Joe Hanna discusses drivers behind PropTech's results, providing an update on the company's growth strategies.
28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
